Bugworks

Bugworks is developing a novel class of broad-spectrum antibiotics to treat bacterial infections and immunotherapies to treat cancer patients.Over several decades, the lack of new antibacterials combined with increased rise of resistance to existing antibiotics, has resulted in a crisis. Bugworks’ cutting-edge innovation has demonstrated promising early results towards launching the world’s first novel class of antibiotics in over 60 years; their asset BWC0977 is currently undergoing clinical trials. Additionally, Bugworks is developing small molecules specifically accentuating the immuno-oncology pathway. Their drug development strategy aligns with our goal of making affordable/accessible solutions for all of humanity in the AMR and Oncology disciplines.